Psychometric Assessment of the Metamorphopsia Questionnaire in Patients with Macular Diseases Receiving Anti-Vascular Endothelial Growth Factor Treatment
Journal of Clinical Medicine · 09.04.2026 · 15 (8) · 2867
DOI: 10.3390/jcm15082867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.04.2026. Verfasst von Francis W B Sanders und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Prince Philip Hospital, Hywel Dda University Health Board, Llanelli SA14 8QF, UK. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HCRW.
Abstract (Originalsprache)
Background
The metamorphopsia questionnaire (MeMoQ) is an established patient-reported outcome measure (PROM) in the context of macular disease. However, its performance has not been proved in those being treated for various macular conditions with intravitreal anti-vascular endothelial growth factor (Anti-VEGF). The objective was to eliminate misfitting items, enhance measurement precision, and ensure optimal response categorisation.
Methods
Rasch analysis was performed iteratively on 2286 responses from patients with macular diseases being treated with Anti-VEGF to optimise the MeMoQ. Fit statistics, reliability indices, person and item separation measures, and principal component analysis (PCA) of residuals were assessed to determine the optimal model. This study was conducted in an outpatient clinic specialising in retinal diseases in Hywel Dda University Health Board.
Results
Misfitting items were removed in successive iterations, leading to optimised category probability curves and stable fit statistics for the MeMoQ. The resulting model for all responses included two final items, with person separation remaining inadequate reducing from 1.23 to 1.12 and reliability from 0.60 to 0.56. Category probability curves demonstrated good ordering of response variables with Andrich thresholds separated by >1.2 logits. In the subgroups of neovascular age-related macular degeneration and diabetic macular oedema person separation remained below two and reliability remained low.
Conclusions
Rasch analysis demonstrated that the MeMoQ was not a valid or reliable PROM in this patient population. Therefore, the MeMoQ may not provide a reliable index of patient’s perception and visual experience when undergoing Anti-VEGF treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Prince Philip Hospital, Hywel Dda University Health Board, Llanelli SA14 8QF, UK.
- School of Optometry and Vision Sciences, Cardiff University, Cardiff CF24 4HQ, UK.
- Department of Ophthalmology, Princess of Wales Hospital, Bridgend CF31 1RQ, UK.
- Wenzhou Medical University, Wenzhou 325015, China.
- Eye and Ear Nose & Throat Hospital, Fudan University, Shanghai 200437, China.
ORCID-Profile: Jennifer H Acton, Barbara Ryan, Colm McAlinden
Förderung
- HCRW
Zitieren
APA
Sanders, F. W. B., Acton, J. H., Ryan, B., & McAlinden, C. (2026). Psychometric Assessment of the Metamorphopsia Questionnaire in Patients with Macular Diseases Receiving Anti-Vascular Endothelial Growth Factor Treatment. Journal of Clinical Medicine, 15(8), 2867. https://doi.org/10.3390/jcm15082867
Vancouver
Sanders FWB, Acton JH, Ryan B, McAlinden C. Psychometric Assessment of the Metamorphopsia Questionnaire in Patients with Macular Diseases Receiving Anti-Vascular Endothelial Growth Factor Treatment. Journal of Clinical Medicine. 2026;15(8):2867. doi:10.3390/jcm15082867
BibTeX
@article{Sanders2026,
author = {Sanders, Francis W B and Acton, Jennifer H and Ryan, Barbara and McAlinden, Colm},
title = {Psychometric Assessment of the Metamorphopsia Questionnaire in Patients with Macular Diseases Receiving Anti-Vascular Endothelial Growth Factor Treatment},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {2867},
doi = {10.3390/jcm15082867}
}
EUVIMED